



## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

## EQA round: AKS1/22 - Basic Clinical Chemistry - Serum

Deadline: 28.01.2022

| Test                             | [unit]   | Comparability |      |        |                  |                  |      |                 |                  |      |      | Traceability     |                  |                  |       |                 |                  |      |     |                  |                  |                  |
|----------------------------------|----------|---------------|------|--------|------------------|------------------|------|-----------------|------------------|------|------|------------------|------------------|------------------|-------|-----------------|------------------|------|-----|------------------|------------------|------------------|
|                                  |          | RoM           | SD   | CV [%] | N <sub>tot</sub> | N <sub>out</sub> | AV   | U <sub>AV</sub> | D <sub>max</sub> | LL   | UL   | N <sub>eva</sub> | N <sub>suc</sub> | S <sub>rel</sub> | AV    | U <sub>AV</sub> | D <sub>max</sub> | LL   | UL  | N <sub>eva</sub> | N <sub>suc</sub> | S <sub>rel</sub> |
| <b>(4) Calcium</b>               | [mmol/L] |               |      |        | 194              |                  |      |                 |                  |      |      | 0                |                  |                  |       |                 |                  |      |     | 194              | 190              | 98%              |
| Samples and groups               |          |               |      |        |                  |                  |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |      |     |                  |                  |                  |
| <b>Sample A</b>                  |          | 2,47          | 0,05 | 2,4    | 194              |                  |      |                 |                  |      |      | 0                | CRV              | 2,452            | 0,037 | 8%              | 2,25             | 2,65 | 194 | 190              | 98%              |                  |
| (4) Photomet. with NM-BAPTA      |          | 2,49          | 0,04 | 2,0    | 74               | 0                |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |      |     |                  | 74               |                  |
| Other                            |          |               |      |        | 3                | 0                |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |      |     |                  | 3                |                  |
| <b>Sample B</b>                  |          | 3,43          | 0,07 | 2,3    | 194              |                  |      |                 |                  |      |      | 0                | CRV              | 3,421            | 0,051 | 8%              | 3,14             | 3,7  | 194 | 194              | 100%             |                  |
| (2) Phot. with o-cresolftalexon  |          | 3,46          | 0,06 | 1,9    | 22               | 0                |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |      |     |                  | 22               |                  |
| (3) Photom. with arsenazo III    |          | 3,40          | 0,09 | 2,8    | 95               | 0                |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |      |     |                  | 95               |                  |
| (4) Photomet. with NM-BAPTA      |          | 3,46          | 0,06 | 1,7    | 74               | 0                |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |      |     |                  | 74               |                  |
| Other                            |          |               |      |        | 3                | 0                |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |      |     |                  | 3                |                  |
|                                  |          |               |      |        |                  |                  |      |                 |                  |      |      |                  | 1x 0, 2x 6       |                  |       |                 |                  |      |     |                  |                  |                  |
| <b>(5) Inorganic phosphate</b>   | [mmol/L] |               |      |        | 184              |                  |      |                 |                  |      |      | 184              | 181              | 98%              |       |                 |                  |      |     |                  |                  | 0                |
| Samples and groups               |          |               |      |        |                  |                  |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |      |     |                  |                  |                  |
| <b>Sample A</b>                  |          | 1,90          | 0,05 | 2,6    | 184              | CVP              | 1,9  | ,0090           | 10%              | 1,71 | 2,09 | 184              | 182              | 99%              |       |                 |                  |      |     |                  |                  | 0                |
| (1) UV-molybdate method          |          | 1,90          | 0,05 | 2,6    | 181              | 0                |      |                 |                  |      |      | 181              |                  |                  |       |                 |                  |      |     |                  |                  |                  |
| Other                            |          |               |      |        | 3                | 0                |      |                 |                  |      |      | 3                |                  |                  |       |                 |                  |      |     |                  |                  |                  |
| <b>Sample B</b>                  |          | 1,33          | 0,03 | 2,8    | 184              | CVP              | 1,33 | ,0068           | 10%              | 1,19 | 1,47 | 184              | 182              | 99%              |       |                 |                  |      |     |                  |                  | 0                |
| (1) UV-molybdate method          |          | 1,33          | 0,03 | 2,9    | 181              | 0                |      |                 |                  |      |      | 181              |                  |                  |       |                 |                  |      |     |                  |                  |                  |
| Other                            |          |               |      |        | 3                | 0                |      |                 |                  |      |      | 3                |                  |                  |       |                 |                  |      |     |                  |                  |                  |
|                                  |          |               |      |        |                  | 3x 2             |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |      |     |                  |                  |                  |
| <b>(6) Iron</b>                  | [µmol/L] |               |      |        | 171              |                  |      |                 |                  |      |      | 171              | 169              | 99%              |       |                 |                  |      |     |                  |                  | 0                |
| Samples and groups               |          |               |      |        |                  |                  |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |      |     |                  |                  |                  |
| <b>Sample A</b>                  |          | 16,2          | 0,57 | 3,5    | 171              | CVP              | 16,2 | 0,11            | 15%              | 13,7 | 18,7 | 171              | 169              | 99%              |       |                 |                  |      |     |                  |                  | 0                |
| (2) Method with ferrozine/ferene |          | 16,2          | 0,61 | 3,8    | 141              | 0                |      |                 |                  |      |      | 141              |                  |                  |       |                 |                  |      |     |                  |                  |                  |
| (4) Method with TPTZ             |          | 15,9          | 0,34 | 2,1    | 30               | 0                |      |                 |                  |      |      | 30               |                  |                  |       |                 |                  |      |     |                  |                  |                  |
| <b>Sample B</b>                  |          | 43,1          | 1,1  | 2,6    | 171              | CVP              | 43,1 | 0,21            | 15%              | 36,6 | 49,6 | 171              | 169              | 99%              |       |                 |                  |      |     |                  |                  | 0                |
| (2) Method with ferrozine/ferene |          | 43,2          | 1,2  | 2,7    | 141              | 0                |      |                 |                  |      |      | 141              |                  |                  |       |                 |                  |      |     |                  |                  |                  |
| (4) Method with TPTZ             |          | 42,9          | 0,87 | 2,0    | 30               | 0                |      |                 |                  |      |      | 30               |                  |                  |       |                 |                  |      |     |                  |                  |                  |
| <b>(7) Magnesium</b>             | [mmol/L] |               |      |        | 184              |                  |      |                 |                  |      |      | 0                |                  |                  |       |                 |                  |      |     | 184              | 182              | 99%              |
| Samples and groups               |          |               |      |        |                  |                  |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |      |     |                  |                  |                  |
| <b>Sample A</b>                  |          | 1,46          | 0,04 | 3,0    | 184              |                  |      |                 |                  |      |      | 0                | CRV              | 1,45             | 0,022 | 15%             | 1,23             | 1,67 | 184 | 182              | 99%              |                  |
| (2) Photometry                   |          | 1,46          | 0,04 | 2,9    | 147              | 0                |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |      |     |                  | 147              |                  |
| (4) UV enzyme method             |          | 1,47          | 0,05 | 3,5    | 37               | 0                |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |      |     |                  | 37               |                  |
| <b>Sample B</b>                  |          | 1,59          | 0,04 | 2,5    | 184              |                  |      |                 |                  |      |      | 0                | CRV              | 1,577            | 0,029 | 15%             | 1,34             | 1,82 | 184 | 183              | 99%              |                  |
| (2) Photometry                   |          | 1,59          | 0,03 | 2,4    | 147              | 0                |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |      |     |                  | 147              |                  |
| (4) UV enzyme method             |          | 1,58          | 0,05 | 3,4    | 37               | 0                |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |      |     |                  | 37               |                  |
| <b>(8) Lithium</b>               | [mmol/L] |               |      |        | 32               |                  |      |                 |                  |      |      | 0                |                  |                  |       |                 |                  |      |     | 32               | 30               | 94%              |
| Samples and groups               |          |               |      |        |                  |                  |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |      |     |                  |                  |                  |
| <b>Sample A</b>                  |          | 1,74          | 0,06 | 3,8    | 32               |                  |      |                 |                  |      |      | 0                | CRV              | 1,793            | 0,027 | 12%             | 1,57             | 2,01 | 32  | 30               | 94%              |                  |
| (3) ISE                          |          | 1,78          | 0,07 | 4,2    | 6                | 0                |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |      |     |                  | 6                |                  |
| (4) Photometry                   |          | 1,73          | 0,04 | 2,7    | 20               | 0                |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |      |     |                  | 20               |                  |
| Other                            |          |               |      |        | 6                | 0                |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |      |     |                  | 6                |                  |
| <b>Sample B</b>                  |          | 1,26          | 0,05 | 3,9    | 32               |                  |      |                 |                  |      |      | 0                | CRV              | 1,285            | 0,034 | 12%             | 1,13             | 1,44 | 32  | 30               | 94%              |                  |
|                                  |          |               |      |        |                  |                  |      |                 |                  |      |      |                  | 3x 1, 3x 2       |                  |       |                 |                  |      |     |                  |                  |                  |

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

## EQA round: AKS1/22 - Basic Clinical Chemistry - Serum

Deadline: 28.01.2022

| Test                          | [unit]    | Comparability |      |        |                  |                  | Traceability |                 |                  |      |      |                  |                  |                  |       |                 |                  |      |    |                  |                  |                  |     |
|-------------------------------|-----------|---------------|------|--------|------------------|------------------|--------------|-----------------|------------------|------|------|------------------|------------------|------------------|-------|-----------------|------------------|------|----|------------------|------------------|------------------|-----|
|                               |           | RoM           | SD   | CV [%] | N <sub>tot</sub> | N <sub>out</sub> | AV           | U <sub>AV</sub> | D <sub>max</sub> | LL   | UL   | N <sub>eva</sub> | N <sub>suc</sub> | S <sub>rel</sub> | AV    | U <sub>AV</sub> | D <sub>max</sub> | LL   | UL | N <sub>eva</sub> | N <sub>suc</sub> | S <sub>rel</sub> |     |
| <b>(8) Lithium</b>            |           |               |      |        | 32               |                  |              |                 |                  |      |      | 0                |                  |                  |       |                 |                  |      |    |                  | 32               | 30               | 94% |
| Samples and groups            | [mmol/L]  |               |      |        |                  |                  |              |                 |                  |      |      |                  |                  |                  |       |                 |                  |      |    |                  |                  |                  |     |
| <b>Sample B</b>               |           | 1,26          | 0,05 | 3,9    | 32               |                  |              |                 |                  |      |      | 0                | CRV              | 1,285            | 0,034 | 12%             | 1,13             | 1,44 |    | 32               | 30               | 94%              |     |
| (3) ISE                       |           | 1,27          | 0,04 | 3,5    | 6                | 0                |              |                 |                  |      |      |                  |                  |                  |       |                 |                  |      |    |                  | 6                |                  |     |
| (4) Photometry                |           | 1,27          | 0,05 | 4,0    | 20               | 0                |              |                 |                  |      |      |                  |                  |                  |       |                 |                  |      |    |                  | 20               |                  |     |
| Other                         |           |               |      |        | 6                | 0                |              |                 |                  |      |      |                  |                  |                  |       |                 |                  |      |    |                  | 6                |                  |     |
|                               |           |               |      |        |                  |                  |              |                 |                  |      |      |                  |                  | 3x 1, 3x 2       |       |                 |                  |      |    |                  |                  |                  |     |
| <b>(9) Total protein</b>      |           |               |      |        | 198              |                  |              |                 |                  |      |      | 0                |                  |                  |       |                 |                  |      |    |                  | 198              | 196              | 99% |
| Samples and groups            | [g/L]     |               |      |        |                  |                  |              |                 |                  |      |      |                  |                  |                  |       |                 |                  |      |    |                  |                  |                  |     |
| <b>Sample A</b>               |           | 53,5          | 1,2  | 2,3    | 198              |                  |              |                 |                  |      |      | 0                | CRV              | 54               | 1,3   | 9%              | 49,1             | 58,9 |    | 198              | 197              | 99%              |     |
| (1) Biuret                    |           | 53,5          | 1,2  | 2,3    | 198              | 0                |              |                 |                  |      |      |                  |                  |                  |       |                 |                  |      |    |                  | 198              |                  |     |
| <b>Sample B</b>               |           | 62,4          | 1,5  | 2,3    | 198              |                  |              |                 |                  |      |      | 0                | CRV              | 62,3             | 1,5   | 9%              | 56,6             | 68   |    | 198              | 196              | 99%              |     |
| (1) Biuret                    |           | 62,4          | 1,5  | 2,3    | 198              | 0                |              |                 |                  |      |      |                  |                  |                  |       |                 |                  |      |    |                  | 198              |                  |     |
| <b>(10) Albumin</b>           |           |               |      |        | 194              |                  |              |                 |                  |      |      | 194              | 190              | 98%              |       |                 |                  |      |    |                  |                  |                  | 0   |
| Samples and groups            | [g/L]     |               |      |        |                  |                  |              |                 |                  |      |      |                  |                  |                  |       |                 |                  |      |    |                  |                  |                  |     |
| <b>Sample A</b>               |           | 34,5          | 1,4  | 3,9    | 194              | CVP              | 34,5         | 0,24            | 10%              | 31   | 38   | 194              | 191              | 98%              |       |                 |                  |      |    |                  |                  |                  | 0   |
| (1) BCG                       |           | 34,6          | 1,3  | 3,6    | 181              | 0                |              |                 |                  |      |      | 181              |                  |                  |       |                 |                  |      |    |                  |                  |                  |     |
| (2) BCP                       |           | 32,4          | 0,94 | 2,9    | 13               | 0                |              |                 |                  |      |      | 13               |                  |                  |       |                 |                  |      |    |                  |                  |                  |     |
| <b>Sample B</b>               |           | 40,3          | 1,5  | 3,7    | 194              | CVP              | 40,3         | 0,26            | 10%              | 36,2 | 44,4 | 194              | 191              | 98%              |       |                 |                  |      |    |                  |                  |                  | 0   |
| (1) BCG                       |           | 40,4          | 1,4  | 3,5    | 181              | 0                |              |                 |                  |      |      | 181              |                  |                  |       |                 |                  |      |    |                  |                  |                  |     |
| (2) BCP                       |           | 38,6          | 1,2  | 3,1    | 13               | 0                |              |                 |                  |      |      | 13               |                  |                  |       |                 |                  |      |    |                  |                  |                  |     |
| <b>(11) Osmolality</b>        |           |               |      |        | 81               |                  |              |                 |                  |      |      | 81               | 80               | 99%              |       |                 |                  |      |    |                  |                  |                  | 0   |
| Samples and groups            | [mmol/kg] |               |      |        |                  |                  |              |                 |                  |      |      |                  |                  |                  |       |                 |                  |      |    |                  |                  |                  |     |
| <b>Sample A</b>               |           | 328           | 4,9  | 1,5    | 81               | CVP              | 328          | 1,3             | 5%               | 311  | 345  | 81               | 80               | 99%              |       |                 |                  |      |    |                  |                  |                  | 0   |
| (1) Osmometer                 |           | 329           | 4,9  | 1,5    | 80               | 0                |              |                 |                  |      |      | 80               |                  |                  |       |                 |                  |      |    |                  |                  |                  |     |
| Other                         |           |               |      |        | 1                | 0                |              |                 |                  |      |      | 1                |                  |                  |       |                 |                  |      |    |                  |                  |                  |     |
| <b>Sample B</b>               |           | 301           | 5,4  | 1,8    | 81               | CVP              | 301          | 1,5             | 5%               | 285  | 317  | 81               | 81               | 100%             |       |                 |                  |      |    |                  |                  |                  | 0   |
| (1) Osmometer                 |           | 301           | 5,3  | 1,8    | 80               | 0                |              |                 |                  |      |      | 80               |                  |                  |       |                 |                  |      |    |                  |                  |                  |     |
| Other                         |           |               |      |        | 1                | 0                |              |                 |                  |      |      | 1                |                  |                  |       |                 |                  |      |    |                  |                  |                  |     |
|                               |           |               |      |        |                  |                  |              |                 |                  |      |      |                  |                  |                  |       |                 |                  |      |    |                  |                  |                  |     |
| <b>(12) Lactate</b>           |           |               |      |        | 92               |                  |              |                 |                  |      |      | 92               | 92               | 100%             |       |                 |                  |      |    |                  |                  |                  | 0   |
| Samples and groups            | [mmol/L]  |               |      |        |                  |                  |              |                 |                  |      |      |                  |                  |                  |       |                 |                  |      |    |                  |                  |                  |     |
| <b>Sample A</b>               |           | 3,45          | 0,11 | 3,3    | 92               | CVP              | 3,45         | 0,029           | 15%              | 2,93 | 3,97 | 92               | 92               | 100%             |       |                 |                  |      |    |                  |                  |                  | 0   |
| (1) UV enzyme method          |           | 3,49          | 0,12 | 3,3    | 33               | 0                |              |                 |                  |      |      | 33               |                  |                  |       |                 |                  |      |    |                  |                  |                  |     |
| (2) Enzyme electrodes         |           | 3,43          | 0,25 | 7,3    | 6                | 0                |              |                 |                  |      |      | 6                |                  |                  |       |                 |                  |      |    |                  |                  |                  |     |
| (3) Photometric enzyme method |           | 3,43          | 0,09 | 2,7    | 53               | 0                |              |                 |                  |      |      | 53               |                  |                  |       |                 |                  |      |    |                  |                  |                  |     |
| <b>Sample B</b>               |           | 3,00          | 0,09 | 3,1    | 92               | CVP              | 3            | 0,024           | 15%              | 2,55 | 3,45 | 92               | 92               | 100%             |       |                 |                  |      |    |                  |                  |                  | 0   |
| (1) UV enzyme method          |           | 3,02          | 0,07 | 2,5    | 33               | 0                |              |                 |                  |      |      | 33               |                  |                  |       |                 |                  |      |    |                  |                  |                  |     |
| (2) Enzyme electrodes         |           | 3,00          | 0,25 | 8,4    | 6                | 0                |              |                 |                  |      |      | 6                |                  |                  |       |                 |                  |      |    |                  |                  |                  |     |
| (3) Photometric enzyme method |           | 2,99          | 0,08 | 3,0    | 53               | 0                |              |                 |                  |      |      | 53               |                  |                  |       |                 |                  |      |    |                  |                  |                  |     |
| <b>(13) Bilirubin total</b>   |           |               |      |        | 207              |                  |              |                 |                  |      |      | 0                |                  |                  |       |                 |                  |      |    |                  | 207              | 203              | 98% |
| Samples and groups            | [µmol/L]  |               |      |        |                  |                  |              |                 |                  |      |      |                  |                  |                  |       |                 |                  |      |    |                  |                  |                  |     |
| <b>Sample A</b>               |           | 60,6          | 5,3  | 8,8    | 207              |                  |              |                 |                  |      |      | 0                | CRV              | 58,7             | 1,3   | 21%             | 46,3             | 71,1 |    | 207              | 204              | 99%              |     |
| (1) Jendrassik-Gróf           |           | 59,8          | 4,0  | 6,7    | 21               | 0                |              |                 |                  |      |      |                  |                  |                  |       |                 |                  |      |    |                  | 21               |                  |     |

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

## EQA round: AKS1/22 - Basic Clinical Chemistry - Serum

Deadline: 28.01.2022

| Test  | [unit]   | Comparability |      |        |                  |                  | Traceability |                 |                  |    |      |                  |                  |                  |       |                 |                  |      |      |                  |                  |                  |      |
|---|----------|---------------|------|--------|------------------|------------------|--------------|-----------------|------------------|----|------|------------------|------------------|------------------|-------|-----------------|------------------|------|------|------------------|------------------|------------------|------|
|   |          | RoM           | SD   | CV [%] | N <sub>tot</sub> | N <sub>out</sub> | AV           | U <sub>AV</sub> | D <sub>max</sub> | LL | UL   | N <sub>eva</sub> | N <sub>suc</sub> | S <sub>rel</sub> | AV    | U <sub>AV</sub> | D <sub>max</sub> | LL   | UL   | N <sub>eva</sub> | N <sub>suc</sub> | S <sub>rel</sub> |      |
| <b>(13) Bilirubin total</b>                                     | [µmol/L] |               |      |        | 207              |                  |              |                 |                  |    |      | 0                |                  |                  |       |                 |                  |      |      |                  | 207              | 203              | 98%  |
| Samples and groups  |          |               |      |        |                  |                  |              |                 |                  |    |      |                  |                  |                  |       |                 |                  |      |      |                  |                  |                  |      |
| <b>Sample A</b>   |          | 60,6          | 5,3  | 8,8    | 207              |                  |              |                 |                  |    |      | 0                | CRV              | 58,7             | 1,3   | 21%             | 46,3             | 71,1 |      | 207              | 204              | 99%              |      |
| (2) DCA, DPD  |          | 60,2          | 5,3  | 8,7    | 162              | 0                |              |                 |                  |    |      |                  |                  |                  |       |                 |                  |      |      |                  | 162              |                  |      |
| (4) Oxidation-reduction methods                                 |          | 64,1          | 4,4  | 6,9    | 24               | 0                |              |                 |                  |    |      |                  |                  |                  |       |                 |                  |      |      |                  | 24               |                  |      |
| <b>Sample B</b>   |          | 31,9          | 3,1  | 9,6    | 207              |                  |              |                 |                  |    |      | 0                | CRV              | 31,2             | 0,70  | 21%             | 24,6             | 37,8 |      | 207              | 204              | 99%              |      |
| (1) Jendrassik-Gróf   |          | 31,6          | 2,5  | 8,0    | 21               | 0                |              |                 |                  |    |      |                  |                  |                  |       |                 |                  |      |      |                  | 21               |                  |      |
| (2) DCA, DPD  |          | 31,7          | 3,1  | 9,8    | 162              | 0                |              |                 |                  |    |      |                  |                  |                  |       |                 |                  |      |      |                  | 162              |                  |      |
| (4) Oxidation-reduction methods                                 |          | 33,8          | 1,9  | 5,7    | 24               | 0                |              |                 |                  |    |      |                  |                  |                  |       |                 |                  |      |      |                  | 24               |                  |      |
| <b>(15) Cholesterol</b>   | [mmol/L] |               |      |        | 196              |                  |              |                 |                  |    |      | 7                | 6                | 86%              |       |                 |                  |      |      |                  | 189              | 177              | 94%  |
| Samples and groups  |          |               |      |        |                  |                  |              |                 |                  |    |      |                  |                  |                  |       |                 |                  |      |      |                  |                  |                  |      |
| <b>Sample A</b>   |          | 3,09          | 0,11 | 3,6    | 196              |                  |              |                 |                  |    |      | 7                | 7                | 100%             |       |                 |                  |      |      |                  | 189              | 180              | 95%  |
| (1) Enzyme method CHOD-PAP                                      |          | 3,09          | 0,10 | 3,3    | 189              | 0                |              |                 |                  |    |      |                  |                  | CRV              | 3,222 | 0,032           | 9%               | 2,93 | 3,52 |                  | 189              |                  |      |
| (1) Enzyme method CHOD-PAP; (149) Siemens (Dade, BN, Dimension) |          | 2,67          | 0,07 | 2,8    | 7                | 0                | CVPG         | 2,67            | 0,072            | 7% | 2,48 | 2,86             |                  | 7                |       |                 |                  |      |      |                  |                  |                  |      |
| <b>Sample B</b>   |          | 3,37          | 0,10 | 3,0    | 196              |                  |              |                 |                  |    |      | 7                | 6                | 86%              |       |                 |                  |      |      |                  | 189              | 184              | 97%  |
| (1) Enzyme method CHOD-PAP                                      |          | 3,38          | 0,09 | 2,8    | 189              | 0                |              |                 |                  |    |      |                  |                  | CRV              | 3,438 | 0,034           | 9%               | 3,12 | 3,75 |                  | 189              |                  |      |
| (1) Enzyme method CHOD-PAP; (149) Siemens (Dade, BN, Dimension) |          | 2,95          | 0,13 | 4,5    | 7                | 0                | CVPG         | 2,95            | 0,13             | 7% | 2,74 | 3,16             |                  | 7                |       |                 |                  |      |      |                  |                  |                  |      |
| <b>(16) Glucose</b>   | [mmol/L] |               |      |        | 208              |                  |              |                 |                  |    |      | 0                |                  |                  |       |                 |                  |      |      |                  | 208              | 202              | 97%  |
| Samples and groups  |          |               |      |        |                  |                  |              |                 |                  |    |      |                  |                  |                  |       |                 |                  |      |      |                  |                  |                  |      |
| <b>Sample A</b>   |          | 5,34          | 0,14 | 2,7    | 208              |                  |              |                 |                  |    |      | 0                |                  | CRV              | 5,369 | 0,054           | 8%               | 4,93 | 5,8  |                  | 208              | 204              | 98%  |
| (1) GOD photometry  |          | 5,38          | 0,15 | 2,8    | 27               | 0                |              |                 |                  |    |      |                  |                  |                  |       |                 |                  |      |      |                  | 27               |                  |      |
| (3) Method with hexokinase                                      |          | 5,33          | 0,14 | 2,6    | 179              | 0                |              |                 |                  |    |      |                  |                  |                  |       |                 |                  |      |      |                  | 179              |                  |      |
| Other   |          |               |      |        | 2                | 0                |              |                 |                  |    |      |                  |                  |                  |       |                 |                  |      |      |                  | 2                |                  |      |
| <b>Sample B</b>   |          | 5,76          | 0,18 | 3,1    | 208              |                  |              |                 |                  |    |      | 0                |                  | 2x2<br>CRV       | 5,824 | 0,058           | 8%               | 5,35 | 6,29 |                  | 208              | 205              | 99%  |
| (1) GOD photometry  |          | 5,86          | 0,14 | 2,5    | 27               | 0                |              |                 |                  |    |      |                  |                  |                  |       |                 |                  |      |      |                  | 27               |                  |      |
| (3) Method with hexokinase                                      |          | 5,74          | 0,16 | 2,9    | 179              | 0                |              |                 |                  |    |      |                  |                  |                  |       |                 |                  |      |      |                  | 179              |                  |      |
| Other   |          |               |      |        | 2                | 0                |              |                 |                  |    |      |                  |                  |                  |       |                 |                  |      |      |                  | 2                |                  |      |
| <b>(17) Uric acid</b>   | [µmol/L] |               |      |        | 202              |                  |              |                 |                  |    |      | 0                |                  |                  |       |                 |                  |      |      |                  | 202              | 200              | 99%  |
| Samples and groups  |          |               |      |        |                  |                  |              |                 |                  |    |      |                  |                  |                  |       |                 |                  |      |      |                  |                  |                  |      |
| <b>Sample A</b>   |          | 243           | 8,7  | 3,6    | 202              |                  |              |                 |                  |    |      | 0                |                  | CRV              | 247,8 | 2,9             | 12%              | 218  | 278  |                  | 202              | 200              | 99%  |
| (2) Enzyme-photomet. m.   |          | 243           | 8,7  | 3,6    | 202              | 0                |              |                 |                  |    |      |                  |                  |                  |       |                 |                  |      |      |                  | 202              |                  |      |
| <b>Sample B</b>   |          | 609           | 19   | 3,0    | 202              |                  |              |                 |                  |    |      | 0                |                  | CRV              | 613   | 6,1             | 12%              | 539  | 687  |                  | 202              | 201              | 100% |
| (2) Enzyme-photomet. m.   |          | 609           | 19   | 3,0    | 202              | 0                |              |                 |                  |    |      |                  |                  |                  |       |                 |                  |      |      |                  | 202              |                  |      |
| <b>(18) Urea</b>  | [mmol/L] |               |      |        | 208              |                  |              |                 |                  |    |      | 0                |                  |                  |       |                 |                  |      |      |                  | 208              | 207              | 100% |
| Samples and groups  |          |               |      |        |                  |                  |              |                 |                  |    |      |                  |                  |                  |       |                 |                  |      |      |                  |                  |                  |      |
| <b>Sample A</b>   |          | 14,9          | 0,49 | 3,3    | 208              |                  |              |                 |                  |    |      | 0                |                  | CRV              | 15,2  | 0,15            | 15%              | 12,9 | 17,5 |                  | 208              | 207              | 100% |
| (1) UV enzymatic m.(GMD)  |          | 14,9          | 0,48 | 3,2    | 206              | 0                |              |                 |                  |    |      |                  |                  |                  |       |                 |                  |      |      |                  | 206              |                  |      |
| Other   |          |               |      |        | 2                | 0                |              |                 |                  |    |      |                  |                  |                  |       |                 |                  |      |      |                  | 2                |                  |      |
| <b>Sample B</b>   |          | 14,8          | 0,53 | 3,6    | 208              |                  |              |                 |                  |    |      | 0                |                  | 2x5<br>CRV       | 15,19 | 0,15            | 15%              | 12,9 | 17,5 |                  | 208              | 208              | 100% |
| (1) UV enzymatic m.(GMD)  |          | 14,8          | 0,53 | 3,6    | 206              | 0                |              |                 |                  |    |      |                  |                  |                  |       |                 |                  |      |      |                  | 206              |                  |      |
| Other   |          |               |      |        | 2                | 0                |              |                 |                  |    |      |                  |                  |                  |       |                 |                  |      |      |                  | 2                |                  |      |
|   |          |               |      |        |                  |                  |              |                 |                  |    |      |                  |                  | 2x5              |       |                 |                  |      |      |                  |                  |                  |      |

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

## EQA round: AKS1/22 - Basic Clinical Chemistry - Serum

Deadline: 28.01.2022

| Test   | [unit]   | Comparability |      |        |                  |                  | Traceability |                 |                  |     |      |                  |                  |                  |       |                 |                  |      |      |                  |                  |                  |     |
|--|----------|---------------|------|--------|------------------|------------------|--------------|-----------------|------------------|-----|------|------------------|------------------|------------------|-------|-----------------|------------------|------|------|------------------|------------------|------------------|-----|
|  |          | RoM           | SD   | CV [%] | N <sub>tot</sub> | N <sub>out</sub> | AV           | U <sub>AV</sub> | D <sub>max</sub> | LL  | UL   | N <sub>eva</sub> | N <sub>suc</sub> | S <sub>rel</sub> | AV    | U <sub>AV</sub> | D <sub>max</sub> | LL   | UL   | N <sub>eva</sub> | N <sub>suc</sub> | S <sub>rel</sub> |     |
| <b>(19) Creatinine</b>                               |          |               |      |        | 210              |                  |              |                 |                  |     |      | 0                |                  |                  |       |                 |                  |      |      | 210              | 208              | 99%              |     |
| Samples and groups                                   | [µmol/L] |               |      |        |                  |                  |              |                 |                  |     |      |                  |                  |                  |       |                 |                  |      |      |                  |                  |                  |     |
| <b>Sample A</b>                                      |          | 491           | 17   | 3,4    | 210              |                  |              |                 |                  |     |      | 0                |                  | CRV              | 489,9 | 5,3             | 13%              | 426  | 554  | 210              | 209              | 100%             |     |
| (1) Jaffe  |          | 484           | 19   | 3,8    | 93               | 0                |              |                 |                  |     |      |                  |                  |                  |       |                 |                  |      |      | 93               |                  |                  |     |
| (3) Enzyme   |          | 497           | 13   | 2,5    | 117              | 0                |              |                 |                  |     |      |                  |                  |                  |       |                 |                  |      |      | 117              |                  |                  |     |
| <b>Sample B</b>                                      |          | 145           | 6,1  | 4,2    | 210              |                  |              |                 |                  |     |      | 0                |                  | CRV              | 143,5 | 1,4             | 13%              | 124  | 163  | 210              | 209              | 100%             |     |
| (1) Jaffe  |          | 145           | 7,8  | 5,4    | 93               | 0                |              |                 |                  |     |      |                  |                  |                  |       |                 |                  |      |      | 93               |                  |                  |     |
| (3) Enzyme   |          | 145           | 4,7  | 3,3    | 117              | 0                |              |                 |                  |     |      |                  |                  |                  |       |                 |                  |      |      | 117              |                  |                  |     |
| <b>(20) Triacylglycerols</b>                         |          |               |      |        | 193              |                  |              |                 |                  |     |      | 0                |                  |                  |       |                 |                  |      |      | 193              | 189              | 98%              |     |
| Samples and groups                                   | [mmol/L] |               |      |        |                  |                  |              |                 |                  |     |      |                  |                  |                  |       |                 |                  |      |      |                  |                  |                  |     |
| <b>Sample A</b>                                      |          | 1,38          | 0,05 | 4,3    | 193              |                  |              |                 |                  |     |      | 0                |                  | CRV              | 1,321 | 0,013           | 15%              | 1,12 | 1,52 | 193              | 189              | 98%              |     |
| (1) Photometric enzyme (GPO-PAP)                     |          | 1,38          | 0,05 | 4,3    | 190              | 0                |              |                 |                  |     |      |                  |                  |                  |       |                 |                  |      |      | 190              |                  |                  |     |
| Other  |          |               |      |        | 3                | 0                |              |                 |                  |     |      |                  |                  |                  |       |                 |                  |      |      |                  | 3                |                  |     |
| <b>Sample B</b>                                      |          | 2,26          | 0,06 | 3,1    | 193              |                  |              |                 |                  |     |      | 0                |                  | CRV              | 2,221 | 0,022           | 15%              | 1,88 | 2,56 | 193              | 192              | 99%              |     |
| (1) Photometric enzyme (GPO-PAP)                     |          | 2,26          | 0,06 | 3,0    | 190              | 0                |              |                 |                  |     |      |                  |                  |                  |       |                 |                  |      |      | 190              |                  |                  |     |
| Other  |          |               |      |        | 3                | 0                |              |                 |                  |     |      |                  |                  |                  |       |                 |                  |      |      |                  | 3                |                  |     |
| <b>(21) ALP</b>                                      |          |               |      |        | 200              |                  |              |                 |                  |     |      | 190              | 185              | 97%              |       |                 |                  |      |      | 200              | 197              | 99%              |     |
| Samples and groups                                   | [µkat/L] |               |      |        |                  |                  |              |                 |                  |     |      |                  |                  |                  |       |                 |                  |      |      |                  |                  |                  |     |
| <b>Sample A</b>                                      |          | 6,94          | 0,55 | 7,9    | 200              |                  |              |                 |                  |     |      | 190              | 187              | 98%              | CRV   | 7,17            | 0,20             | 20%  | 5,73 | 8,61             | 200              | 197              | 99% |
| (3) IFCC method; (1) Abbott                          |          | 7,15          | 0,35 | 5,0    | 38               | 0                | CVPG         | 7,15            | 0,14             | 15% | 6,07 | 8,23             |                  |                  |       |                 |                  |      |      | 38               |                  |                  |     |
| (3) IFCC method                                      |          | 6,93          | 0,54 | 7,8    | 199              | 0                |              |                 |                  |     |      |                  |                  |                  |       |                 |                  |      |      |                  | 199              |                  |     |
| (3) IFCC method; (46) Erba Lachema                   |          | 7,48          | 0,47 | 6,3    | 8                | 0                | CVPG         | 7,55            | 0,42             | 15% | 6,41 | 8,69             |                  |                  |       |                 |                  |      |      | 8                |                  |                  |     |
| (3) IFCC method; (58) Beckman Coulter (AU)           |          | 7,80          | 0,48 | 6,2    | 27               | 0                | CVPG         | 7,8             | 0,23             | 15% | 6,63 | 8,97             |                  |                  |       |                 |                  |      |      | 27               |                  |                  |     |
| (3) IFCC method; (60) Roche                          |          | 6,59          | 0,27 | 4,2    | 82               | 0                | CVPG         | 6,59            | 0,074            | 15% | 5,6  | 7,58             |                  |                  |       |                 |                  |      |      | 82               |                  |                  |     |
| (3) IFCC method; (149) Siemens (Dade, BN, Dimension) |          | 6,71          | 0,25 | 3,7    | 9                | 0                | CVPG         | 6,71            | 0,31             | 15% | 5,7  | 7,72             |                  |                  |       |                 |                  |      |      | 9                |                  |                  |     |
| (3) IFCC method; (162) Siemens (Atellica)            |          | 6,75          | 0,22 | 3,3    | 13               | 0                | CVPG         | 6,75            | 0,15             | 15% | 5,73 | 7,77             |                  |                  |       |                 |                  |      |      | 13               |                  |                  |     |
| (3) IFCC method; (177) Mindray                       |          | 7,41          | 0,36 | 4,8    | 5                | 0                | CVPG         | 7,41            | 1,0              | 15% | 6,29 | 8,53             |                  |                  |       |                 |                  |      |      | 5                |                  |                  |     |
| (3) IFCC method; (179) Siemens                       |          | 6,90          | 0,59 | 8,5    | 7                | 0                | CVPG         | 6,9             | 0,57             | 15% | 5,86 | 7,94             |                  |                  |       |                 |                  |      |      | 7                |                  |                  |     |
| Other  |          |               |      |        | 1                | 0                |              |                 |                  |     |      |                  |                  |                  |       |                 |                  |      |      |                  | 1                |                  |     |
| <b>Sample B</b>                                      |          | 4,29          | 0,28 | 6,6    | 200              |                  |              |                 |                  |     |      | 190              | 185              | 97%              | CRV   | 4,45            | 0,13             | 20%  | 3,56 | 5,34             | 200              | 198              | 99% |
| (3) IFCC method; (1) Abbott                          |          | 4,38          | 0,22 | 5,1    | 38               | 0                | CVPG         | 4,38            | 0,089            | 15% | 3,72 | 5,04             |                  |                  |       |                 |                  |      |      | 38               |                  |                  |     |
| (3) IFCC method                                      |          | 4,29          | 0,28 | 6,5    | 199              | 0                |              |                 |                  |     |      |                  |                  |                  |       |                 |                  |      |      |                  | 199              |                  |     |
| (3) IFCC method; (46) Erba Lachema                   |          | 4,58          | 0,26 | 5,7    | 8                | 0                | CVPG         | 4,59            | 0,28             | 15% | 3,9  | 5,28             |                  |                  |       |                 |                  |      |      | 8                |                  |                  |     |
| (3) IFCC method; (58) Beckman Coulter (AU)           |          | 4,66          | 0,28 | 6,0    | 27               | 0                | CVPG         | 4,66            | 0,13             | 15% | 3,96 | 5,36             |                  |                  |       |                 |                  |      |      | 27               |                  |                  |     |
| (3) IFCC method; (60) Roche                          |          | 4,11          | 0,16 | 4,0    | 82               | 0                | CVPG         | 4,11            | 0,045            | 15% | 3,49 | 4,73             |                  |                  |       |                 |                  |      |      | 82               |                  |                  |     |
| (3) IFCC method; (149) Siemens (Dade, BN, Dimension) |          | 4,19          | 0,08 | 2,1    | 9                | 0                | CVPG         | 4,19            | 0,11             | 15% | 3,56 | 4,82             |                  |                  |       |                 |                  |      |      | 9                |                  |                  |     |
| (3) IFCC method; (162) Siemens (Atellica)            |          | 4,22          | 0,07 | 1,7    | 13               | 0                | CVPG         | 4,22            | 0,048            | 15% | 3,58 | 4,86             |                  |                  |       |                 |                  |      |      | 13               |                  |                  |     |
| (3) IFCC method; (177) Mindray                       |          | 4,37          | 0,24 | 5,6    | 5                | 0                | CVPG         | 4,37            | 0,69             | 15% | 3,71 | 5,03             |                  |                  |       |                 |                  |      |      | 5                |                  |                  |     |
| (3) IFCC method; (179) Siemens                       |          | 4,49          | 0,29 | 6,4    | 7                | 0                | CVPG         | 4,49            | 0,28             | 15% | 3,81 | 5,17             |                  |                  |       |                 |                  |      |      | 7                |                  |                  |     |
| Other  |          |               |      |        | 1                | 0                |              |                 |                  |     |      |                  |                  |                  |       |                 |                  |      |      |                  | 1                |                  |     |
|  |          |               |      |        |                  |                  |              |                 |                  |     |      |                  |                  |                  |       |                 |                  |      |      |                  |                  |                  |     |

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

## EQA round: AKS1/22 - Basic Clinical Chemistry - Serum

Deadline: 28.01.2022

| Test   | [unit]   | Comparability |      |        |                  |                  |      |                 |                  |      |      | Traceability     |                  |                  |       |                 |                  |     |      |                  |                  |                  |      |
|--|----------|---------------|------|--------|------------------|------------------|------|-----------------|------------------|------|------|------------------|------------------|------------------|-------|-----------------|------------------|-----|------|------------------|------------------|------------------|------|
|  |          | RoM           | SD   | CV [%] | N <sub>tot</sub> | N <sub>out</sub> | AV   | U <sub>AV</sub> | D <sub>max</sub> | LL   | UL   | N <sub>eva</sub> | N <sub>suc</sub> | S <sub>rel</sub> | AV    | U <sub>AV</sub> | D <sub>max</sub> | LL  | UL   | N <sub>eva</sub> | N <sub>suc</sub> | S <sub>rel</sub> |      |
| <b>(22) alpha-amylase</b>                            |          |               |      |        | 197              |                  |      |                 |                  |      |      | 6                | 6                | 100%             |       |                 |                  |     |      | 191              | 189              | 99%              |      |
| Samples and groups                                   | [µkat/L] |               |      |        |                  |                  |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |     |      |                  |                  |                  |      |
| <b>Sample A</b>                                      |          | 3,34          | 0,21 | 6,2    | 197              |                  |      |                 |                  |      |      | 6                | 6                | 100%             |       |                 |                  |     |      | 191              | 190              | 99%              |      |
| (1) IFCC method                                      |          | 3,33          | 0,20 | 5,9    | 190              | 0                |      |                 |                  |      |      |                  |                  |                  | CRV   | 3,321           | 0,095            | 15% | 2,82 | 3,82             | 190              |                  |      |
| (1) IFCC method; (149) Siemens (Dade, BN, Dimension) |          | 3,92          | 0,04 | 1,1    | 6                | 0                | CVPG | 3,92            | 0,062            | 8,8% | 3,57 | 4,27             | 6                |                  |       |                 |                  |     |      |                  |                  |                  |      |
| Other  |          |               |      |        | 1                | 0                |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |     |      |                  | 1                |                  |      |
| -----  |          |               |      |        |                  |                  |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |     |      |                  |                  |                  |      |
| <b>Sample B</b>                                      |          | 8,64          | 0,61 | 7,0    | 197              |                  |      |                 |                  |      |      | 6                | 6                | 100%             |       |                 |                  |     |      | 191              | 190              | 99%              |      |
| (1) IFCC method                                      |          | 8,60          | 0,58 | 6,7    | 190              | 0                |      |                 |                  |      |      |                  |                  |                  | CRV   | 8,49            | 0,23             | 15% | 7,21 | 9,77             | 190              |                  |      |
| (1) IFCC method; (149) Siemens (Dade, BN, Dimension) |          | 10,5          | 0,22 | 2,1    | 6                | 0                | CVPG | 10,5            | 0,31             | 8,8% | 9,57 | 11,5             | 6                |                  |       |                 |                  |     |      |                  |                  |                  |      |
| Other  |          |               |      |        | 1                | 0                |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |     |      |                  | 1                |                  |      |
| -----  |          |               |      |        |                  |                  |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |     |      |                  |                  |                  |      |
|  |          |               |      |        |                  |                  |      |                 |                  |      |      |                  |                  |                  | 1x 99 |                 |                  |     |      |                  |                  |                  |      |
| <b>(23) AST</b>                                      |          |               |      |        | 207              |                  |      |                 |                  |      |      | 0                |                  |                  |       |                 |                  |     |      | 207              | 197              | 95%              |      |
| Samples and groups                                   | [µkat/L] |               |      |        |                  |                  |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |     |      |                  |                  |                  |      |
| <b>Sample A</b>                                      |          | 1,91          | 0,10 | 5,3    | 207              |                  |      |                 |                  |      |      | 0                |                  |                  | CRV   | 1,88            | 0,041            | 15% | 1,59 | 2,17             | 207              | 200              | 97%  |
| (1) IFCC method                                      |          | 1,91          | 0,10 | 5,2    | 206              | 0                |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |     |      |                  | 206              |                  |      |
| Other  |          |               |      |        | 1                | 0                |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |     |      |                  | 1                |                  |      |
| -----  |          |               |      |        |                  |                  |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |     |      |                  |                  |                  |      |
| <b>Sample B</b>                                      |          | 3,22          | 0,15 | 4,8    | 207              |                  |      |                 |                  |      |      | 0                |                  |                  | CRV   | 3,235           | 0,071            | 15% | 2,74 | 3,73             | 207              | 198              | 96%  |
| (1) IFCC method                                      |          | 3,22          | 0,15 | 4,7    | 206              | 0                |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |     |      |                  | 206              |                  |      |
| Other  |          |               |      |        | 1                | 0                |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |     |      |                  | 1                |                  |      |
| -----  |          |               |      |        |                  |                  |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |     |      |                  |                  |                  |      |
|  |          |               |      |        |                  |                  |      |                 |                  |      |      |                  |                  |                  | 1x 99 |                 |                  |     |      |                  |                  |                  |      |
| <b>(24) ALT</b>                                      |          |               |      |        | 208              |                  |      |                 |                  |      |      | 0                |                  |                  |       |                 |                  |     |      | 208              | 203              | 98%              |      |
| Samples and groups                                   | [µkat/L] |               |      |        |                  |                  |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |     |      |                  |                  |                  |      |
| <b>Sample A</b>                                      |          | 3,63          | 0,18 | 4,9    | 208              |                  |      |                 |                  |      |      | 0                |                  |                  | CRV   | 3,606           | 0,089            | 15% | 3,06 | 4,15             | 208              | 205              | 99%  |
| (1) IFCC method                                      |          | 3,63          | 0,18 | 4,9    | 207              | 0                |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |     |      |                  | 207              |                  |      |
| Other  |          |               |      |        | 1                | 0                |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |     |      |                  | 1                |                  |      |
| -----  |          |               |      |        |                  |                  |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |     |      |                  |                  |                  |      |
| <b>Sample B</b>                                      |          | 1,33          | 0,08 | 6,6    | 208              |                  |      |                 |                  |      |      | 0                |                  |                  | CRV   | 1,327           | 0,032            | 15% | 1,12 | 1,53             | 208              | 203              | 98%  |
| (1) IFCC method                                      |          | 1,33          | 0,08 | 6,6    | 207              | 0                |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |     |      |                  | 207              |                  |      |
| Other  |          |               |      |        | 1                | 0                |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |     |      |                  | 1                |                  |      |
| -----  |          |               |      |        |                  |                  |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |     |      |                  |                  |                  |      |
|  |          |               |      |        |                  |                  |      |                 |                  |      |      |                  |                  |                  | 1x 99 |                 |                  |     |      |                  |                  |                  |      |
| <b>(26) CK</b>                                       |          |               |      |        | 189              |                  |      |                 |                  |      |      | 0                |                  |                  |       |                 |                  |     |      | 189              | 187              | 99%              |      |
| Samples and groups                                   | [µkat/L] |               |      |        |                  |                  |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |     |      |                  |                  |                  |      |
| <b>Sample A</b>                                      |          | 9,81          | 0,67 | 6,8    | 189              |                  |      |                 |                  |      |      | 0                |                  |                  | CRV   | 10,33           | 0,27             | 20% | 8,26 | 12,4             | 189              | 187              | 99%  |
| (1) IFCC method                                      |          | 9,81          | 0,67 | 6,8    | 189              | 0                |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |     |      |                  | 189              |                  |      |
| <b>Sample B</b>                                      |          | 4,46          | 0,30 | 6,8    | 189              |                  |      |                 |                  |      |      | 0                |                  |                  | CRV   | 4,75            | 0,17             | 20% | 3,8  | 5,7              | 189              | 188              | 99%  |
| (1) IFCC method                                      |          | 4,46          | 0,30 | 6,8    | 189              | 0                |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |     |      |                  | 189              |                  |      |
| -----  |          |               |      |        |                  |                  |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |     |      |                  |                  |                  |      |
| <b>(27) gamma-GT</b>                                 |          |               |      |        | 202              |                  |      |                 |                  |      |      | 0                |                  |                  |       |                 |                  |     |      | 202              | 200              | 99%              |      |
| Samples and groups                                   | [µkat/L] |               |      |        |                  |                  |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |     |      |                  |                  |                  |      |
| <b>Sample A</b>                                      |          | 2,98          | 0,13 | 4,4    | 202              |                  |      |                 |                  |      |      | 0                |                  |                  | CRV   | 2,978           | 0,073            | 15% | 2,53 | 3,43             | 202              | 201              | 100% |
| (1) IFCC method                                      |          | 2,98          | 0,13 | 4,4    | 201              | 0                |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |     |      |                  | 201              |                  |      |
| Other  |          |               |      |        | 1                | 0                |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |     |      |                  | 1                |                  |      |
| -----  |          |               |      |        |                  |                  |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |     |      |                  |                  |                  |      |
| <b>Sample B</b>                                      |          | 3,47          | 0,15 | 4,4    | 202              |                  |      |                 |                  |      |      | 0                |                  |                  | CRV   | 3,466           | 0,088            | 15% | 2,94 | 3,99             | 202              | 200              | 99%  |
| (1) IFCC method                                      |          | 3,47          | 0,15 | 4,3    | 201              | 0                |      |                 |                  |      |      |                  |                  |                  |       |                 |                  |     |      |                  | 201              |                  |      |

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

## EQA round: AKS1/22 - Basic Clinical Chemistry - Serum

Deadline: 28.01.2022

| Test   | [unit]   | Comparability |      |        |                  |                  |      |                 |                  |     |       | Traceability     |                  |                  |       |                 |                  |      |      |                  |                  |                  |     |     |
|--|----------|---------------|------|--------|------------------|------------------|------|-----------------|------------------|-----|-------|------------------|------------------|------------------|-------|-----------------|------------------|------|------|------------------|------------------|------------------|-----|-----|
|  |          | RoM           | SD   | CV [%] | N <sub>tot</sub> | N <sub>out</sub> | AV   | U <sub>AV</sub> | D <sub>max</sub> | LL  | UL    | N <sub>eva</sub> | N <sub>suc</sub> | S <sub>rel</sub> | AV    | U <sub>AV</sub> | D <sub>max</sub> | LL   | UL   | N <sub>eva</sub> | N <sub>suc</sub> | S <sub>rel</sub> |     |     |
| <b>(27) gamma-GT</b>                         |          |               |      |        | 202              |                  |      |                 |                  |     |       |                  | 0                |                  |       |                 |                  |      |      |                  | 202              | 200              | 99% |     |
| Samples and groups                           | [µkat/L] |               |      |        |                  |                  |      |                 |                  |     |       |                  |                  |                  |       |                 |                  |      |      |                  |                  |                  |     |     |
| <b>Sample B</b>                              |          | 3,47          | 0,15 | 4,4    | 202              |                  |      |                 |                  |     |       |                  | 0                | CRV              | 3,466 | 0,088           | 15%              | 2,94 | 3,99 |                  | 202              | 200              | 99% |     |
| Other  |          |               |      |        | 1                | 0                |      |                 |                  |     |       |                  |                  | 1x 99            |       |                 |                  |      |      |                  |                  | 1                |     |     |
| <b>(28) LD</b>                               |          |               |      |        | 155              |                  |      |                 |                  |     |       |                  | 0                |                  |       |                 |                  |      |      |                  |                  | 155              | 152 | 98% |
| Samples and groups                           | [µkat/L] |               |      |        |                  |                  |      |                 |                  |     |       |                  |                  |                  |       |                 |                  |      |      |                  |                  |                  |     |     |
| <b>Sample A</b>                              |          | 4,24          | 0,17 | 4,0    | 155              |                  |      |                 |                  |     |       |                  | 0                | CRV              | 4,24  | 0,100           | 18%              | 3,47 | 5,01 |                  | 155              | 152              | 98% |     |
| (3) IFCC method                              |          | 4,24          | 0,17 | 4,0    | 154              | 0                |      |                 |                  |     |       |                  |                  |                  |       |                 |                  |      |      |                  |                  | 154              |     |     |
| Other  |          |               |      |        | 1                | 0                |      |                 |                  |     |       |                  |                  | 1x 99            |       |                 |                  |      |      |                  |                  | 1                |     |     |
| <b>Sample B</b>                              |          | 7,49          | 0,22 | 3,0    | 155              |                  |      |                 |                  |     |       |                  | 0                | CRV              | 7,43  | 0,17            | 18%              | 6,09 | 8,77 |                  | 155              | 153              | 99% |     |
| (3) IFCC method                              |          | 7,49          | 0,22 | 2,9    | 154              | 0                |      |                 |                  |     |       |                  |                  |                  |       |                 |                  |      |      |                  |                  | 154              |     |     |
| Other  |          |               |      |        | 1                | 0                |      |                 |                  |     |       |                  |                  | 1x 99            |       |                 |                  |      |      |                  |                  | 1                |     |     |
| <b>(29) Lipase</b>                           |          |               |      |        | 117              |                  |      |                 |                  |     |       |                  | 97               | 94               | 97%   |                 |                  |      |      |                  |                  |                  | 0   |     |
| Samples and groups                           | [µkat/L] |               |      |        |                  |                  |      |                 |                  |     |       |                  |                  |                  |       |                 |                  |      |      |                  |                  |                  |     |     |
| <b>Sample A</b>                              |          | 3,44          | 0,40 | 12     | 117              |                  |      |                 |                  |     |       |                  | 97               | 94               | 97%   |                 |                  |      |      |                  |                  |                  | 0   |     |
| (0) Not specified; (1) Abbott                |          | 3,38          | 0,18 | 5,3    | 14               | 0                | CVPG | 3,38            | 0,12             | 24% | 2,56  | 4,2              | 14               |                  |       |                 |                  |      |      |                  |                  |                  |     |     |
| (0) Not specified; (58) Beckman Coulter (AU) |          | 3,59          | 0,18 | 4,9    | 21               | 0                | CVPG | 3,59            | 0,094            | 24% | 2,72  | 4,46             | 21               |                  |       |                 |                  |      |      |                  |                  |                  |     |     |
| (0) Not specified; (60) Roche                |          | 3,31          | 0,30 | 8,9    | 50               | 0                | CVPG | 3,31            | 0,10             | 24% | 2,51  | 4,11             | 50               |                  |       |                 |                  |      |      |                  |                  |                  |     |     |
| (0) Not specified; (162) Siemens (Atellica)  |          | 3,90          | 0,16 | 4,2    | 12               | 0                | CVPG | 3,9             | 0,12             | 24% | 2,96  | 4,84             | 12               |                  |       |                 |                  |      |      |                  |                  |                  |     |     |
| Other  |          |               |      |        | 20               | 0                |      |                 |                  |     |       |                  |                  |                  |       |                 |                  |      |      |                  |                  |                  |     |     |
|  |          |               |      |        |                  |                  |      |                 |                  |     |       |                  |                  |                  |       |                 |                  |      |      |                  |                  |                  |     |     |
| <b>Sample B</b>                              |          | 1,57          | 0,18 | 11     | 117              |                  |      |                 |                  |     |       |                  | 97               | 95               | 98%   |                 |                  |      |      |                  |                  |                  | 0   |     |
| (0) Not specified; (1) Abbott                |          | 1,62          | 0,11 | 6,6    | 14               | 0                | CVPG | 1,62            | 0,069            | 24% | 1,23  | 2,01             | 14               |                  |       |                 |                  |      |      |                  |                  |                  |     |     |
| (0) Not specified; (58) Beckman Coulter (AU) |          | 1,71          | 0,09 | 5,5    | 21               | 0                | CVPG | 1,71            | 0,050            | 24% | 1,29  | 2,13             | 21               |                  |       |                 |                  |      |      |                  |                  |                  |     |     |
| (0) Not specified; (60) Roche                |          | 1,49          | 0,11 | 7,2    | 50               | 0                | CVPG | 1,49            | 0,037            | 24% | 1,13  | 1,85             | 50               |                  |       |                 |                  |      |      |                  |                  |                  |     |     |
| (0) Not specified; (162) Siemens (Atellica)  |          | 1,71          | 0,05 | 3,4    | 12               | 0                | CVPG | 1,71            | 0,041            | 24% | 1,29  | 2,13             | 12               |                  |       |                 |                  |      |      |                  |                  |                  |     |     |
| Other  |          |               |      |        | 20               | 0                |      |                 |                  |     |       |                  |                  |                  |       |                 |                  |      |      |                  |                  |                  |     |     |
|  |          |               |      |        |                  |                  |      |                 |                  |     |       |                  |                  |                  |       |                 |                  |      |      |                  |                  |                  |     |     |
| <b>(30) Cholinesterase</b>                   |          |               |      |        | 68               |                  |      |                 |                  |     |       |                  | 66               | 63               | 95%   |                 |                  |      |      |                  |                  |                  | 0   |     |
| Samples and groups                           | [µkat/L] |               |      |        |                  |                  |      |                 |                  |     |       |                  |                  |                  |       |                 |                  |      |      |                  |                  |                  |     |     |
| <b>Sample A</b>                              |          | 95,7          | 4,5  | 4,7    | 68               |                  |      |                 |                  |     |       |                  | 66               | 63               | 95%   |                 |                  |      |      |                  |                  |                  | 0   |     |
| (1) Standard method                          |          | 95,4          | 4,2  | 4,4    | 65               | 0                | CVP  | 95,4            | 1,2              | 12% | 83,9  | 107              | 65               |                  |       |                 |                  |      |      |                  |                  |                  |     |     |
| Other  |          |               |      |        | 3                | 0                |      |                 |                  |     |       |                  | 1                |                  |       |                 |                  |      |      |                  |                  |                  |     |     |
|  |          |               |      |        |                  |                  |      |                 |                  |     |       |                  |                  |                  |       |                 |                  |      |      |                  |                  |                  |     |     |
| <b>Sample B</b>                              |          | 117           | 5,5  | 4,7    | 68               |                  |      |                 |                  |     |       |                  | 66               | 63               | 95%   |                 |                  |      |      |                  |                  |                  | 0   |     |
| (1) Standard method                          |          | 117           | 5,1  | 4,4    | 65               | 0                | CVP  | 117             | 1,5              | 12% | 102   | 132              | 65               |                  |       |                 |                  |      |      |                  |                  |                  |     |     |
| Other  |          |               |      |        | 3                | 0                |      |                 |                  |     |       |                  | 1                |                  |       |                 |                  |      |      |                  |                  |                  |     |     |
|  |          |               |      |        |                  |                  |      |                 |                  |     |       |                  |                  |                  |       |                 |                  |      |      |                  |                  |                  |     |     |
| <b>(31) Albumin (elpho)</b>                  |          |               |      |        | 57               |                  |      |                 |                  |     |       |                  | 57               | 55               | 96%   |                 |                  |      |      |                  |                  |                  | 0   |     |
| Samples and groups                           | [-]      |               |      |        |                  |                  |      |                 |                  |     |       |                  |                  |                  |       |                 |                  |      |      |                  |                  |                  |     |     |
| <b>Sample A</b>                              |          | 0,628         | 0,03 | 5,4    | 57               |                  | CVP  | 0,628           | 0,011            | 15% | 0,533 | 0,723            | 57               | 55               | 96%   |                 |                  |      |      |                  |                  |                  | 0   |     |
| (0) Not specified                            |          | 0,628         | 0,03 | 5,4    | 57               | 1                |      |                 |                  |     |       |                  | 57               |                  |       |                 |                  |      |      |                  |                  |                  |     |     |
| <b>Sample B</b>                              |          | 0,634         | 0,03 | 5,4    | 57               |                  | CVP  | 0,634           | 0,011            | 15% | 0,538 | 0,73             | 57               | 55               | 96%   |                 |                  |      |      |                  |                  |                  | 0   |     |

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

## EQA round: AKS1/22 - Basic Clinical Chemistry - Serum

Deadline: 28.01.2022

| Test                                 | [unit]   | Comparability |      |        |                  |                  | Traceability |                 |                  |       |       |                  |                  |                  |    |                 |                  |    |    |                  |                  |                  |   |
|--------------------------------------|----------|---------------|------|--------|------------------|------------------|--------------|-----------------|------------------|-------|-------|------------------|------------------|------------------|----|-----------------|------------------|----|----|------------------|------------------|------------------|---|
|                                      |          | RoM           | SD   | CV [%] | N <sub>tot</sub> | N <sub>out</sub> | AV           | U <sub>AV</sub> | D <sub>max</sub> | LL    | UL    | N <sub>eva</sub> | N <sub>suc</sub> | S <sub>rel</sub> | AV | U <sub>AV</sub> | D <sub>max</sub> | LL | UL | N <sub>eva</sub> | N <sub>suc</sub> | S <sub>rel</sub> |   |
| <b>(31) Albumin (elpho)</b>          |          |               |      |        | 57               |                  |              |                 |                  |       |       | 57               | 55               | 96%              |    |                 |                  |    |    |                  |                  |                  | 0 |
| Samples and groups                   | [-]      |               |      |        |                  |                  |              |                 |                  |       |       |                  |                  |                  |    |                 |                  |    |    |                  |                  |                  |   |
| <b>Sample B</b>                      |          | 0,634         | 0,03 | 5,4    | 57               | CVP              | 0,634        | 0,011           | 15%              | 0,538 | 0,73  | 57               | 55               | 96%              |    |                 |                  |    |    |                  |                  |                  | 0 |
| (0) Not specified                    |          | 0,634         | 0,03 | 5,4    | 57               | 1                |              |                 |                  |       |       | 57               |                  |                  |    |                 |                  |    |    |                  |                  |                  |   |
| <b>(32) gamma-globuline (elpho)</b>  |          |               |      |        | 57               |                  |              |                 |                  |       |       | 57               | 54               | 95%              |    |                 |                  |    |    |                  |                  |                  | 0 |
| Samples and groups                   | [-]      |               |      |        |                  |                  |              |                 |                  |       |       |                  |                  |                  |    |                 |                  |    |    |                  |                  |                  |   |
| <b>Sample A</b>                      |          | 0,133         | 0,01 | 11     | 57               | CVP              | 0,133        | ,0049           | 30%              | 0,093 | 0,173 | 57               | 55               | 96%              |    |                 |                  |    |    |                  |                  |                  | 0 |
| (0) Not specified                    |          | 0,133         | 0,01 | 11     | 57               | 1                |              |                 |                  |       |       | 57               |                  |                  |    |                 |                  |    |    |                  |                  |                  |   |
| <b>Sample B</b>                      |          | 0,129         | 0,01 | 10     | 57               | CVP              | 0,129        | ,0043           | 30%              | 0,09  | 0,168 | 57               | 54               | 95%              |    |                 |                  |    |    |                  |                  |                  | 0 |
| (0) Not specified                    |          | 0,129         | 0,01 | 10     | 57               | 1                |              |                 |                  |       |       | 57               |                  |                  |    |                 |                  |    |    |                  |                  |                  |   |
| <b>(35) alpha-amylase pancreatic</b> |          |               |      |        | 76               |                  |              |                 |                  |       |       | 76               | 76               | 100%             |    |                 |                  |    |    |                  |                  |                  | 0 |
| Samples and groups                   | [µkat/L] |               |      |        |                  |                  |              |                 |                  |       |       |                  |                  |                  |    |                 |                  |    |    |                  |                  |                  |   |
| <b>Sample A</b>                      |          | 2,76          | 0,10 | 3,7    | 76               | CVP              | 2,76         | 0,029           | 18%              | 2,26  | 3,26  | 76               | 76               | 100%             |    |                 |                  |    |    |                  |                  |                  | 0 |
| (1) With IFCC calibration            |          | 2,76          | 0,10 | 3,7    | 76               | 0                |              |                 |                  |       |       | 76               |                  |                  |    |                 |                  |    |    |                  |                  |                  |   |
| <b>Sample B</b>                      |          | 7,67          | 0,32 | 4,2    | 76               | CVP              | 7,67         | 0,090           | 18%              | 6,28  | 9,06  | 76               | 76               | 100%             |    |                 |                  |    |    |                  |                  |                  | 0 |
| (1) With IFCC calibration            |          | 7,67          | 0,32 | 4,2    | 76               | 0                |              |                 |                  |       |       | 76               |                  |                  |    |                 |                  |    |    |                  |                  |                  |   |
| <b>(36) Calcium ionised</b>          |          |               |      |        | 43               |                  |              |                 |                  |       |       | 43               | 39               | 91%              |    |                 |                  |    |    |                  |                  |                  | 0 |
| Samples and groups                   | [mmol/L] |               |      |        |                  |                  |              |                 |                  |       |       |                  |                  |                  |    |                 |                  |    |    |                  |                  |                  |   |
| <b>Sample A</b>                      |          | 1,66          | 0,07 | 4,7    | 43               | CVP              | 1,66         | 0,029           | 10%              | 1,49  | 1,83  | 43               | 39               | 91%              |    |                 |                  |    |    |                  |                  |                  | 0 |
| (2) Direct ISE                       |          | 1,67          | 0,07 | 4,5    | 37               | 0                |              |                 |                  |       |       | 37               |                  |                  |    |                 |                  |    |    |                  |                  |                  |   |
| Other                                |          |               |      |        | 6                | 0                |              |                 |                  |       |       | 6                |                  |                  |    |                 |                  |    |    |                  |                  |                  |   |
|                                      |          |               |      |        |                  |                  | 3x 0, 3x 1   |                 |                  |       |       |                  |                  |                  |    |                 |                  |    |    |                  |                  |                  |   |
| <b>Sample B</b>                      |          | 2,28          | 0,08 | 3,8    | 43               | CVP              | 2,28         | 0,032           | 10%              | 2,05  | 2,51  | 43               | 40               | 93%              |    |                 |                  |    |    |                  |                  |                  | 0 |
| (2) Direct ISE                       |          | 2,29          | 0,07 | 3,2    | 37               | 0                |              |                 |                  |       |       | 37               |                  |                  |    |                 |                  |    |    |                  |                  |                  |   |
| Other                                |          |               |      |        | 6                | 0                |              |                 |                  |       |       | 6                |                  |                  |    |                 |                  |    |    |                  |                  |                  |   |
|                                      |          |               |      |        |                  |                  | 3x 0, 3x 1   |                 |                  |       |       |                  |                  |                  |    |                 |                  |    |    |                  |                  |                  |   |

st\_kn\_np

End of report

Printed: 03.02.2022